Medicare Program; Inflation Reduction Act of 2022 (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Request
What happened
The Centers for Medicare & Medicaid Services (CMS) is requesting public comments on its draft guidance for the Medicare Drug Price Negotiation Program. This guidance focuses on how drug manufacturers will implement the maximum fair price for drugs in 2028 under the Inflation Reduction Act of 2022 (IRA). The document was signed by Donald Trump and formally approved by Dr. Mehmet Oz, Administrator of CMS. Comments must be received by September 18, 2026, and can be sent to [email protected].
Why it matters
This allows the public to provide input on how new rules to lower prescription drug costs will be put into practice. The program aims to negotiate maximum fair prices for certain high-cost drugs, potentially making them more affordable for Medicare beneficiaries.
Who it affects
- ›Drug manufacturers
- ›Medicare beneficiaries
- ›Public citizens commenting on guidance
- ›Department of Health and Human Services (HHS)
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.